Improvement of self-reported physical functioning with tiotropium/olodaterol in Central and Eastern European COPD patients

<b>Introduction:</b> Patients treated with tiotropium/olodaterol (T/O) show significant improvement in exercise capacity in clinical studies, but real-world data are lacking. <b>Aim:</b> Evaluate perceived limitation with physical functioning (PF), general patient condition and patient satisfaction in stable COPD post treatment with T/O in a real-world setting. <b>Methods:</b> Open-label observational study in 9 Central and Eastern European countries evaluated patients with COPD receiving T/O delivered via Respimat^® for 6 weeks. At study start and end, patients completed PF-10 questionnaire and general patient condition was reviewed using the 8-point Physician’s Global Evaluation (PGE) scale. Patient treatment and device satisfaction were assessed at last visit. <b>Results:</b> Based on GOLD 2017, of 7,443 patients enrolled, 48.9% were GOLD B; 24.2% GOLD D; 21.8% GOLD A; and 5.1% GOLD C. Of the 7,218 who completed the study, therapeutic success (10-point increase in PF-10¹) was achieved in 67.8% (95% CI 66.7–68.8%) of patients, and in 64.3% (95% CI 63.0–65.6%) with infrequent (≤1) and 76.1% (95% CI 74.3–77.9%) with frequent (≥2) exacerbations (p&lt;0.0001). A shift towards PGE improvement was seen from baseline (56.3% scored 3–4 satisfactory, 31.4% scored 5–7 good/excellent) to study end (16.0% scored 3–4, 78.7% scored 5–7). Satisfaction with treatment/device was high: 81% of patients satisfied/very satisfied with T/O treatment, 85% with inhaling from the Respimat device and 84% with device handling. <b>Conclusions:</b> Treatment with tiotropium/olodaterol, under real-life conditions, improved self-reported physical functioning and general condition in patients with COPD.¹Mean (SD) at baseline: 46.11 (23.30).